The DOI matches its Crossref record; 92 of the 92 references it cites were found in a registry or an index.
Biologic and therapeutic role of HER2 in cancer
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Molecular portraits of human breast tumours
Perou, C. M., Sørlie, T., Eisen, M. B., van de Rijn, M., Jeffrey, S. S., Rees, C. A., Pollack, J. R., Ross, D. T., Johnsen, H., Akslen, L. A., et al. (2000) · Nature · doi:10.1038/35021093 · Cited by 16,261
Slamon, D. J., Leyland-Jones, B., Shak, S., Fuchs, H., Paton, V., Bajamonde, A., Fleming, T., Eiermann, W., Wolter, J., Pegram, M., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200103153441101 · Cited by 11,500 · cited 2×
“In that context, clinical studies have demonstrated a synergistic action between trastuzumab and the drug taxane (Slamon et al., 2001), which induces suppression of adaptive immunity, but selectively increases NK activity (Tsavaris et al., 2002).”
Sørlie, T., Perou, C. M., Tibshirani, R., Aas, T., Geisler, S., Johnsen, H., Hastie, T., Eisen, M. B., van de Rijn, M., Jeffrey, S. S., et al. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.191367098 · Cited by 10,938
Gene expression profiling predicts clinical outcome of breast cancer
van 't Veer, L. J., Dai, H., van de Vijver, M. J., He, Y. D., Hart, A. A. M., Mao, M., Peterse, H. L., van der Kooy, K., Marton, M. J., Witteveen, A. T., et al. (2002) · Nature · doi:10.1038/415530a · Cited by 9,536
Studies of the HER-2/ neu Proto-Oncogene in Human Breast and Ovarian Cancer
Slamon, D. J., Godolphin, W., Jones, L. A., Holt, J. A., Wong, S. G., Keith, D. E., Levin, W. J., Stuart, S. G., Udove, J., Ullrich, A., et al. (1989) · Science · doi:10.1126/science.2470152 · Cited by 6,816
Tamoxifen for early breast cancer: an overview of the randomised trials
(1998) · The Lancet · doi:10.1016/s0140-6736(97)11423-4 · Cited by 4,085
Inhibitory Fc receptors modulate in vivo cytoxicity against tumor targets
Clynes, R. A., Towers, T. L., Presta, L. G., & Ravetch, J. V. (2000) · Nature Medicine · doi:10.1038/74704 · Cited by 2,768 · cited 1×
“In contrast, the activity of trastuzumab examined in animal models was found to depend on the engagement of Fc-receptor expressing lymphocytes (Clynes et al., 2000), indicating ADCC as the major mechanism of antibody action.”
BackgroundCobleigh, M. A., Vogel, C. L., Tripathy, D., Robert, N. J., Scholl, S., Fehrenbacher, L., Wolter, J. M., Paton, V., Shak, S., Lieberman, G., et al. (1999) · Journal of Clinical Oncology · doi:10.1200/jco.1999.17.9.2639 · Cited by 2,765
Ullrich, A., Coussens, L., Hayflick, J. S., Dull, T. J., Gray, A., Tam, A. W., Lee, J., Yarden, Y., Libermann, T. A., Schlessinger, J., et al. (1984) · Nature · doi:10.1038/309418a0 · Cited by 2,752
Focan, C., Steinberg, S. M., Blichert-Toft, M., Forbes, J., Collins, R. D., Anderson, S., Margreiter, R., Harwood, C. S., Andersen, K., Beighton, G., et al. (1998) · PubMed · Cited by 2,146
Humanization of an anti-p185HER2 antibody for human cancer therapy.
Carter, P., Presta, L., Gorman, C. M., Ridgway, J. B., Henner, D., Wong, W. L., Rowland, A. M., Kotts, C., Carver, M. E., & Shepard, H. M. (1992) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.89.10.4285 · Cited by 1,918
Vogel, C. L., Cobleigh, M. A., Tripathy, D., Gutheil, J. C., Harris, L. N., Fehrenbacher, L., Slamon, D. J., Murphy, M., Novotny, W. F., Burchmore, M., et al. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.2002.20.3.719 · Cited by 1,860
Coussens, L., Yang-Feng, T. L., Liao, Y.-C., Chen, E., Gray, A., McGrath, J., Seeburg, P. H., Libermann, T. A., Schlessinger, J., Francke, U., et al. (1985) · Science · doi:10.1126/science.2999974 · Cited by 1,814
Graus-Porta, D. (1997) · The EMBO Journal · doi:10.1093/emboj/16.7.1647 · Cited by 1,590
The EGFR family and its ligands in human cancer
Yarden, Y. (2001) · European Journal of Cancer · doi:10.1016/s0959-8049(01)00230-1 · Cited by 1,587
Requirement for neuregulin receptor erbB2 in neural and cardiac development
Lee, K.-F., Simon, H., Chen, H., Bates, B., Hung, M.-C., & Hauser, C. (1995) · Nature · doi:10.1038/378394a0 · Cited by 1,290
Multiple essential functions of neuregulin in development
Meyer, D., & Birchmeier, C. (1995) · Nature · doi:10.1038/378386a0 · Cited by 1,262
Targeted Disruption of Mouse EGF receptor: Effect of Genetic Background on Mutant Phenotype
Threadgill, D. W., Dlugosz, A. A., Hansen, L. A., Tennenbaum, T., Lichti, U., Yee, D., LaMantia, C., Mourton, T., Herrup, K., Harris, R. C., et al. (1995) · Science · doi:10.1126/science.7618084 · Cited by 1,179
Aberrant neural and cardiac development in mice lacking the ErbB4 neuregulin receptor
Gassmann, M., Casagranda, F., Orioli, D., Simon, H., Lai, C., Klein, R., & Lemke, G. (1995) · Nature · doi:10.1038/378390a0 · Cited by 1,148
Mayordomo, J. I., Zorina, T., Storkus, W. J., Zitvogel, L., Celluzzi, C., Falo, L. D., Melief, C. J., Ildstad, S. T., Martin Kast, W., Deleo, A. B., et al. (1995) · Nature Medicine · doi:10.1038/nm1295-1297 · Cited by 1,074
Tzahar, E., Waterman, H., Chen, X., Levkowitz, G., Karunagaran, D., Lavi, S., Ratzkin, B. J., & Yarden, Y. (1996) · Molecular and Cellular Biology · doi:10.1128/mcb.16.10.5276 · Cited by 1,036
erb B-2 Is a Potent Oncogene When Overexpressed in NIH/3T3 Cells
Di Fiore, P. P., Pierce, J. H., Kraus, M. H., Segatto, O., King, C. R., & Aaronson, S. A. (1987) · Science · doi:10.1126/science.2885917 · Cited by 1,010
Zitvogel, L., Mayordomo, J. I., Tjandrawan, T., DeLeo, A. B., Clarke, M. R., Lotze, M. T., & Storkus, W. J. (1996) · The Journal of experimental medicine · doi:10.1084/jem.183.1.87 · Cited by 828
Press, M. F., Bernstein, L., Thomas, P. A., Meisner, L. F., Zhou, J. Y., Ma, Y., Hung, G., Robinson, R. A., Harris, C., El-Naggar, A., et al. (1997) · Journal of Clinical Oncology · doi:10.1200/jco.1997.15.8.2894 · Cited by 802
Debnath, J., Mills, K. R., Collins, N. L., Reginato, M. J., Muthuswamy, S. K., & Brugge, J. S. (2002) · Cell · doi:10.1016/s0092-8674(02)01001-2 · Cited by 763
Hudziak, R. M., Lewis, G. D., Winget, M., Fendly, B. M., Shepard, H. M., & Ullrich, A. (1989) · Molecular and Cellular Biology · doi:10.1128/mcb.9.3.1165 · Cited by 749
Kraus, M. H., Issing, W., Miki, T., Popescu, N. C., & Aaronson, S. A. (1989) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.86.23.9193 · Cited by 737
ErbB-2 is a common auxiliary subunit of NDF and EGF receptors: implications for breast cancer.
Karunagaran, D., Tzahar, E., Beerli, R. R., Chen, X., Graus-Porta, D., Ratzkin, B. J., Seger, R., Hynes, N. E., & Yarden, Y. (1996) · The EMBO Journal · doi:10.1002/j.1460-2075.1996.tb00356.x · Cited by 674
Prenzel, N., Fischer, O. M., Streit, S., Hart, S., & Ullrich, A. (2001) · Endocrine-related cancer · doi:10.1677/erc.0.0080011 · Cited by 673
Molecular mechanisms underlying ErbB2/HER2 action in breast cancer
Harari, D., & Yarden, Y. (2000) · Oncogene · doi:10.1038/sj.onc.1203973 · Cited by 633
Herceptin acts as an anti-angiogenic cocktail
Izumi, Y., Xu, L., di Tomaso, E., Fukumura, D., & Jain, R. K. (2002) · Nature · doi:10.1038/416279b · Cited by 623
erbB-2, p53, and Efficacy of Adjuvant Therapy in Lymph Node-Positive Breast Cancer
Thor, A. D., Berry, D. A., Budman, D. R., Muss, H. B., Kute, T., Henderson, I. C., Barcos, M., Cirrincione, C., Edgerton, S., Allred, C., et al. (1998) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/90.18.1346 · Cited by 612
Konecny, G., Pauletti, G., Pegram, M., Untch, M., Dandekar, S., Aguilar, Z., Wilson, C., Rong, H.-M., Bauerfeind, I., Felber, M., et al. (2003) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/95.2.142 · Cited by 588
ErbB2, but not ErbB1, reinitiates proliferation and induces luminal repopulation in epithelial acini
Muthuswamy, S. K., Li, D., Lelievre, S., Bissell, M. J., & Brugge, J. S. (2001) · Nature Cell Biology · doi:10.1038/ncb0901-785 · Cited by 554
Peles, E., Bacus, S. S., Koski, R. A., Lu, H. S., Wen, D., Ogden, S. G., Levy, R. B., & Yarden, Y. (1992) · Cell · doi:10.1016/0092-8674(92)90131-u · Cited by 524 · cited 1×
“Nevertheless, HER2 signaling is carefully regulated in cells and excess signaling induces apoptosis in cells carrying a wild-type p53 gene (Peles et al., 1992; Daly et al., 1997, 1999; Giani et al., 1998).”
BackgroundPaik, S., Bryant, J., Tan-Chiu, E., Romond, E., Hiller, W., Park, K., Brown, A., Yothers, G., Anderson, S., Smith, R., et al. (2002) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/94.11.852 · Cited by 484
Heregulin induces tyrosine phosphorylation of HER4/p180erbB4
Plowman, G. D., Green, J. M., Culouscou, J.-M., Carlton, G. W., Rothwell, V. M., & Buckley, S. (1993) · Nature · doi:10.1038/366473a0 · Cited by 441
Knutson, K. L., Schiffman, K., & Disis, M. L. (2001) · Journal of Clinical Investigation · doi:10.1172/jci11752 · Cited by 439
In vivo natural killer cell activities revealed by natural killer cell-deficient mice
Kim, S., Iizuka, K., Aguila, H. L., Weissman, I. L., & Yokoyama, W. M. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.050588297 · Cited by 424
Disis, M. L., Gooley, T. A., Rinn, K., Davis, D., Piepkorn, M., Cheever, M. A., Knutson, K. L., & Schiffman, K. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.2002.06.171 · Cited by 423
Concordance Between Local and Central Laboratory HER2 Testing in the Breast Intergroup Trial N9831
Roche, P. C., Suman, V. J., Jenkins, R. B., Davidson, N. E., Martino, S., Kaufman, P. A., Addo, F. K., Murphy, B., Ingle, J. N., & Perez, E. A. (2002) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/94.11.855 · Cited by 390
Rovero, S., Amici, A., Carlo, E. D., Bei, R., Nanni, P., Quaglino, E., Porcedda, P., Boggio, K., Smorlesi, A., Lollini, P.-L., et al. (2000) · The Journal of Immunology · doi:10.4049/jimmunol.165.9.5133 · Cited by 356
Disis, M. L., Pupa, S. M., Gralow, J. R., Dittadi, R., Menard, S., & Cheever, M. A. (1997) · Journal of Clinical Oncology · doi:10.1200/jco.1997.15.11.3363 · Cited by 345
Self-citationImmune changes in patients with advanced breast cancer undergoing chemotherapy with taxanes
Tsavaris, N., Kosmas, C., Vadiaka, M., Kanelopoulos, P., & Boulamatsis, D. (2002) · British Journal of Cancer · doi:10.1038/sj.bjc.6600347 · Cited by 343 · cited 1×
“In that context, clinical studies have demonstrated a synergistic action between trastuzumab and the drug taxane (Slamon et al., 2001), which induces suppression of adaptive immunity, but selectively increases NK activity (Tsavaris et al., 2002).”
BackgroundA strain-independent postnatal neurodegeneration in mice lacking the EGF receptor
Sibilia, M. (1998) · The EMBO Journal · doi:10.1093/emboj/17.3.719 · Cited by 325
The influence of surgical trauma on experimental metastasis
Murthy, S. M., Goldschmidt, R. A., Rao, L. N., Ammirati, M., Buchmann, T., & Scanlon, E. F. (1989) · Cancer · doi:10.1002/1097-0142(19891115)64:10<2035::aid-cncr2820641012>3.0.co;2-l · Cited by 310
Epidermal growth factor receptor family in lung cancer and premalignancy
Franklin, W. A., Veve, R., Hirsch, F. R., Helfrich, B. A., & Bunn, P. A. (2002) · Seminars in Oncology · doi:10.1053/sonc.2002.31520 · Cited by 306
Role of HER2 gene overexpression in breast carcinoma
M�nard, S., Tagliabue, E., Campiglio, M., & Pupa, S. M. (2000) · Journal of Cellular Physiology · doi:10.1002/(sici)1097-4652(200002)182:2<150::aid-jcp3>3.0.co;2-e · Cited by 303
Self-citationMonoclonal antibody therapy of human cancer: Taking the HER2 protooncogene to the clinic
Shepard, H. M., Lewis, G. D., Sarup, J. C., Fendly, B. M., Maneval, D., Mordenti, J., Figari, I., Kotts, C. E., Palladino, M. A., Ullrich, A., et al. (1991) · Journal of Clinical Immunology · doi:10.1007/bf00918679 · Cited by 294
Böcker, W., Moll, R., Poremba, C., Holland, R., van Diest, P. J., Dervan, P., Bürger, H., Wai, D., Ina Diallo, R., Brandt, B., et al. (2002) · Laboratory Investigation · doi:10.1097/01.lab.0000017371.72714.c5 · Cited by 283
Burstein, H. J., Harris, L. N., Gelman, R., Lester, S. C., Nunes, R. A., Kaelin, C. M., Parker, L. M., Ellisen, L. W., Kuter, I., Gadd, M. A., et al. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.03.124 · Cited by 280
Allgayer, H., Babic, R., Gruetzner, K. U., Tarabichi, A., Schildberg, F. W., & Heiss, M. M. (2000) · Journal of Clinical Oncology · doi:10.1200/jco.2000.18.11.2201 · Cited by 276
HER2 as a Prognostic Factor in Breast Cancer
Ménard, S., Fortis, S., Castiglioni, F., Agresti, R., & Balsari, A. (2001) · Oncology · doi:10.1159/000055404 · Cited by 268
Self-citationRilke, F., Colnaghi, M. I., Cascinelli, N., Andreola, S., Baldini, M. T., Bufalino, R., Porta, G. D., Ménard, S., Pierotti, M. A., & Testori, A. (1991) · International Journal of Cancer · doi:10.1002/ijc.2910490109 · Cited by 259
Self-citationLudewig, B., Ochsenbein, A. F., Odermatt, B., Paulin, D., Hengartner, H., & Zinkernagel, R. M. (2000) · The Journal of Experimental Medicine · doi:10.1084/jem.191.5.795 · Cited by 252
Evaluation of HER-2/neu gene amplification and protein expression in non-small cell lung carcinomas
Hirsch, F. R., Varella-Garcia, M., Franklin, W. A., Veve, R., Chen, L., Helfrich, B., Zeng, C., Baron, A., & Bunn, P. A. (2002) · British Journal of Cancer · doi:10.1038/sj.bjc.6600286 · Cited by 246
Nanni, P., Nicoletti, G., De Giovanni, C., Landuzzi, L., Di Carlo, E., Cavallo, F., Pupa, S. M., Rossi, I., Colombo, M. P., Ricci, C., et al. (2001) · The Journal of Experimental Medicine · doi:10.1084/jem.194.9.1195 · Cited by 230
Self-citationHaynes, N. M., Trapani, J. A., Teng, M. W. L., Jackson, J. T., Cerruti, L., Jane, S. M., Kershaw, M. H., Smyth, M. J., & Darcy, P. K. (2002) · Blood · doi:10.1182/blood-2002-04-1041 · Cited by 197
‘Accidental’ anti-angiogenic drugs
Kerbel, R. S., Viloria-Petit, A., Klement, G., & Rak, J. (2000) · European Journal of Cancer · doi:10.1016/s0959-8049(00)00092-7 · Cited by 182
Cavallo, F., Giovarelli, M., Forni, G., Signorelli, P., Musiani, P., Modesti, A., Brunda, M. J., & Colombo, M. P. (1997) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/89.14.1049 · Cited by 171
HER-2/neu Protein: A Target for Antigen-Specific Immunotherapy of Human Cancer
(1997) · Advances in Cancer Research · doi:10.1016/s0065-230x(08)60103-7 · Cited by 166
Liu, Y., El-Ashry, D., Chen, D., Ding, I. Y. F., & Kern, F. G. (1995) · Breast Cancer Research and Treatment · doi:10.1007/bf00665783 · Cited by 163
Nagata, Y., Furugen, R., Hiasa, A., Ikeda, H., Ohta, N., Furukawa, K., Nakamura, H., Furukawa, K., Kanematsu, T., & Shiku, H. (1997) · The Journal of Immunology · doi:10.4049/jimmunol.159.3.1336 · Cited by 156
Gambaletta, D., Marchetti, A., Benedetti, L., Mercurio, A. M., Sacchi, A., & Falcioni, R. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.275.14.10604 · Cited by 152
Ménard, S., Valagussa, P., Pilotti, S., Gianni, L., Biganzoli, E. M., Boracchi, P., Tomasic, G., Casalini, P., Marubini, E., COLNAGHI, M. I., et al. (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.2.329 · Cited by 149
Self-citationMénard, S., Casalini, P., Campiglio, M., Pupa, S. M., Agresti, R., & Tagliabue, E. (2001) · Annals of Oncology · doi:10.1093/annonc/12.suppl_1.s15 · Cited by 149
Self-citationDittmar, T., Husemann, A., Schewe, Y., Nofer, J., Niggemann, B., Zänker, K. S., & Brandt, B. (2002) · The FASEB Journal · doi:10.1096/fj.02-0096fje · Cited by 137
Clinical cancer vaccine trials
Jäger, E., Jäger, D., & Knuth, A. K. (2002) · Current Opinion in Immunology · doi:10.1016/s0952-7915(02)00318-7 · Cited by 131
Ohashi, P. S., & DeFranco, A. L. (2002) · Current Opinion in Immunology · doi:10.1016/s0952-7915(02)00406-5 · Cited by 123
Finn, O. J., & Forni, G. (2002) · Current Opinion in Immunology · doi:10.1016/s0952-7915(02)00317-5 · Cited by 107
Waterman, H., Alroy, I., Strano, S., Seger, R., & Yarden, Y. (1999) · The EMBO Journal · doi:10.1093/emboj/18.12.3348 · Cited by 103
Cancer Cell Motility—On the Road from c-erbB-2 Receptor Steered Signaling to Actin Reorganization
Feldner, J., & Brandt, B. (2002) · Experimental Cell Research · doi:10.1006/excr.2001.5385 · Cited by 101
Prognostic and predictive value of HER2/neu oncogene in breast cancer
Masood, S., & Bui, M. M. (2002) · Microscopy Research and Technique · doi:10.1002/jemt.10181 · Cited by 101
Daly, J. M., Olayioye, M. A., Wong, A. M.-L., Neve, R. M., Lane, H. A., Maurer, F. G., & Hynes, N. E. (1999) · Oncogene · doi:10.1038/sj.onc.1202700 · Cited by 101
The Tumor-Promoting Effect of Wounding: A Possible Role for TGF-β-lnduced Stromal Alterations
Sieweke, M. H., & Bissell, M. J. (1994) · Critical Reviews™ in Oncogenesis · doi:10.1615/critrevoncog.v5.i2-3.90 · Cited by 99
HER2 Overexpression and Doxorubicin in Adjuvant Chemotherapy for Resectable Breast Cancer
Moliterni, A., Ménard, S., Valagussa, P., Biganzoli, E. M., Boracchi, P., Balsari, A., Casalini, P., Tomasic, G., Marubini, E., Pilotti, S., et al. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.04.021 · Cited by 99
Self-citationCellular immunity to the Her-2/neu protooncogene
Kiessling, R. W., Wei, W. Z., Herrmann, F., Lindencrona, J. A., Choudhury, A., Kono, K., & Seliger, B. (2002) · Advances in cancer research · doi:10.1016/s0065-230x(02)85004-7 · Cited by 84
O‐charoenrat, P., Rhys‐Evans, P. H., Court, W. J., Box, G., & Eccles, S. A. (1999) · Clinical & Experimental Metastasis · doi:10.1023/a:1006751016860 · Cited by 76
Grunt, T. W., Saceda, M., Martin, M. B., Lupu, R., Dittrich, E., Krupitza, G., Harant, H., Huber, H. P., & Dittrich, C. (1995) · International Journal of Cancer · doi:10.1002/ijc.2910630417 · Cited by 72
Gancberg, D., Järvinen, T. A. H., Leo, A. D., Rouas, G., Cardoso, F., Paesmans, M., Verhest, A. P., Piccart, M. J., Isola, J. J., & Larsimont, D. (2002) · Breast Cancer Research and Treatment · doi:10.1023/a:1016146130767 · Cited by 70
Nakamura, H., Saji, H., Ogata, A., Hosaka, M., Hagiwara, M., Kawasaki, N., & Kato, H. (2002) · International Journal of Cancer · doi:10.1002/ijc.10795 · Cited by 67
Giani, C., Casalini, P., Pupa, S. M., Vecchi, R. D., Ardini, E., COLNAGHI, M. I., Giordano, A., & Ménard, S. (1998) · Oncogene · doi:10.1038/sj.onc.1201954 · Cited by 58
Self-citationRole of proliferation in HER2 status predicted response to doxorubicin
Campiglio, M., Somenzi, G., Olgiati, C., Beretta, G. L., Balsari, A., Zaffaroni, N., Valagussa, P., & Ménard, S. (2003) · International Journal of Cancer · doi:10.1002/ijc.11113 · Cited by 57
Self-citationRole of p53 in HER2-induced Proliferation or Apoptosis
Casalini, P., Botta, L., & Ménard, S. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m009732200 · Cited by 47
Self-citationCell Biology of Lymphatic Metastasis The Potential Role of c-erbB Oncogene Signalling
Eccles, S. A. (2000) · Recent results in cancer research/Recent Results in Cancer Research · doi:10.1007/978-3-642-57151-0_5 · Cited by 40
Foy, T. M., Fanger, G. R., Hand, S. L., Gerard, C. M., Bruck, C., & Cheever, M. A. (2002) · Seminars in Oncology · doi:10.1016/s0093-7754(02)70127-9 · Cited by 37
Prevention of spontaneous mammary adenocarcinoma in HER‐2/neu transgenic mice by foreign DNA
Sfondrini, L., Besusso, D., Rumio, C., Rodolfo, M., Ménard, S., & Balsari, A. (2002) · The FASEB Journal · doi:10.1096/fj.02-0383com · Cited by 33
Self-citationHER-2/neu expression in germ cell tumours
Soule, S. E. (2002) · Journal of Clinical Pathology · doi:10.1136/jcp.55.9.656 · Cited by 25
Nicolini, G., Miloso, M., Moroni, M. C., Beguinot, L., & Scotto, L. (1996) · Journal of Biological Chemistry · doi:10.1074/jbc.271.47.30290 · Cited by 18
Laminin activates the p185HER2 oncoprotein and mediates growth inhibition of breast carcinoma cells
Tagliabue, E., Ardini, E., Pellegrini, R., Campiglio, M., Bufalino, R., Jeschke, M. G., Groner, B., Colnaghi, M., & Ménard, S. (1996) · British Journal of Cancer · doi:10.1038/bjc.1996.560 · Cited by 16
Self-citationColocalization of the p185HER2 oncoprotein and integrin α6β4 in Calu‐3 lung carcinoma cells
Campiglio, M., Tagliabue, E., Uppugunduri, S., Pellegrini, R., Martignone, S., Ménard, S., COLNAGHI, M. I., Lombardi, L., & Marchisio, P. C. (1994) · Journal of Cellular Biochemistry · doi:10.1002/jcb.240550402 · Cited by 16
Self-citationZuev, Y. S. (2002) · International Polymer Science and Technology · doi:10.1177/0307174x0202900615 · Cited by 5
Cited by
Iqbal, N., & Iqbal, N. (2014) · Molecular Biology International · doi:10.1155/2014/852748 · Cited by 1,381
Kinase-targeted cancer therapies: progress, challenges and future directions
Bhullar, K. S., Lagarón, N. O., McGowan, E. M., Parmar, I., Jha, A., Hubbard, B. P., & Rupasinghe, H. P. V. (2018) · Molecular Cancer · doi:10.1186/s12943-018-0804-2 · Cited by 1,245
Glycocalyx engineering reveals a Siglec-based mechanism for NK cell immunoevasion
Hudak, J. E., Canham, S. M., & Bertozzi, C. R. (2014) · Nature Chemical Biology · doi:10.1038/nchembio.1388 · Cited by 485
Deregulated expression of the PER1 , PER2 and PER3 genes in breast cancers
Chen, S.-T., Choo, K.-B., Hou, M.-F., Yeh, K.-T., Kuo, S.-J., & Chang, J.-G. (2005) · Carcinogenesis · doi:10.1093/carcin/bgi075 · Cited by 423
Boku, N. (2014) · Gastric Cancer · doi:10.1007/s10120-013-0252-z · Cited by 351
Metadata
- Authors
- Ménard, S., Pupa, S. M., Campiglio, M., & Tagliabue, E.
- Venue
- Oncogene
- Published
- 2003-09-29
- Volume
- 22
- Issue
- 42
- Pages
- 6570-6578
- ISSN
- 0950-9232 (ISSN-L)
- 1476-5594
- OpenAlex
- W2074270635
- Cited by
- 432
- References
- 92
- FWCI
- 8.72
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.